PDB
MCID: PGT001
MIFTS: 59

Paget's Disease of Bone (PDB) malady

Categories: Rare diseases, Genetic diseases, Bone diseases

Aliases & Classifications for Paget's Disease of Bone

Aliases & Descriptions for Paget's Disease of Bone:

Name: Paget's Disease of Bone 12 25 41 14
Paget Disease of Bone 12 50 24 25 13
Osteitis Deformans 12 50 25 42 69
Familial Paget Disease of Bone 50 29
Osseous Paget's Disease 12 25
Paget Disease, Bone 25 29
Pdb 50 25
Familial Paget's Disease of Bone 12
Paget Disease of Bone, Familial 50
Paget's Bone Disease 12
Pagets Bone Disease 52

Classifications:



External Ids:

Disease Ontology 12 DOID:5408
ICD10 33 M88
MeSH 42 D010001
NCIt 47 C3292
UMLS 69 C0029401

Summaries for Paget's Disease of Bone

MedlinePlus : 41 paget's disease of bone causes your bones to grow too large and weak. they also might break easily. the disease can lead to other health problems, too, such as arthritis and hearing loss. you can have paget's disease in any bone, but it is most common in the spine, pelvis, skull, and legs. the disease might affect one or several bones, but not your entire skeleton. more men than women have the disease. it is most common in older people. no one knows what causes paget's disease. in some cases, a virus might be responsible. it tends to run in families. many people do not know they have paget's disease because their symptoms are mild. for others, symptoms can include pain enlarged bones broken bones damaged cartilage in joints doctors use blood tests and imaging tests to diagnose paget's disease. early diagnosis and treatment can prevent some symptoms from getting worse. treatments include medicines and sometimes surgery. a good diet and exercise might also help. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Paget's Disease of Bone, also known as paget disease of bone, is related to mammary paget's disease and paget disease of bone 3, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Paget's Disease of Bone is SQSTM1 (Sequestosome 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and RANK Signaling in Osteoclasts. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin, and related phenotypes are immune system and limbs/digits/tail

Disease Ontology : 12 A bone formation disease that has material basis in hyperactive osteoclast which results_in abnormal osteoblast bone formation located in skull, located in pelvis, located in vertebral column, located in set of limbs.

Genetics Home Reference : 25 Paget disease of bone is a disorder that causes bones to grow larger and weaker than normal. Affected bones may be misshapen and easily broken (fractured).

NIH Rare Diseases : 50 paget disease of bone is a disorder that involves abnormal bone destruction and regrowth, which results in deformity. this condition can affect any of the bones in the body; but most people have it in their spine, pelvis, skull, or leg bones. the disease may affect only one bone or several bones; but it does not affect the entire skeleton. bones with paget disease may break more easily, and the disease can lead to other health problems. the cause of paget disease is unknown, although it may be associated with faulty genes or viral infections early in life. last updated: 12/12/2011

Related Diseases for Paget's Disease of Bone

Diseases related to Paget's Disease of Bone via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Related Disease Score Top Affiliating Genes
1 mammary paget's disease 11.4
2 paget disease of bone 3 11.2
3 paget disease of bone 5, juvenile-onset 10.3
4 phospholipase a2, group iv a, deficiency of 10.3 PDB6 ZNF687
5 cocaine dependence 10.3 SQSTM1 TNFRSF11A TNFRSF11B
6 hepatic fibrosis renal cysts mental retardation 10.3 TNFRSF11A TNFRSF11B TNFSF11
7 polyomavirus allograft nephropathy 10.3 TNFRSF11A TNFRSF11B TNFSF11
8 chromosome 16q22 deletion syndrome 10.3 CALCA TNFRSF11A TNFSF11
9 extrahepatic bile duct leiomyosarcoma 10.2 TNFRSF11A TNFSF11
10 familial mediterranean fever, ad 10.2 BGLAP TNFSF11
11 osteopetrosis, autosomal recessive 7 10.2 SQSTM1 TNFRSF11A TNFRSF11B TNFSF11
12 adrenal cortical adenoma 10.2 SQSTM1 VCP
13 phka2-related phosphorylase kinase deficiency 10.2 CALCA TNFRSF11A TNFRSF11B TNFSF11
14 birk-barel mental retardation dysmorphism syndrome 10.2 CALCA TNFRSF11A TNFRSF11B TNFSF11
15 cortical blindness 10.2 CSF1 TNFRSF11B TNFSF11
16 glossitis 10.2 CALCA TNFRSF11A TNFRSF11B TNFSF11
17 epilepsy, idiopathic generalized 14 10.2 BGLAP TNFRSF11A TNFRSF11B TNFSF11
18 celiac disease 10.2 BGLAP TNFRSF11B TNFSF11
19 intrahepatic cholestasis 10.2 BGLAP TNFRSF11A TNFRSF11B TNFSF11
20 exudative vitreoretinopathy 4 10.2 CSF1 TNFRSF11B TNFSF11
21 pancreatic ductal adenocarcinoma 10.1 CSF1 TNFRSF11A TNFSF11
22 peripheral scars of retina 10.1 TNFRSF11B TNFSF11
23 hypochondrogenesis 10.0 BGLAP PTH
24 cranial nerve palsy 10.0 B2M TNFRSF11B TNFSF11
25 microcephaly 10, primary, autosomal recessive 10.0 ACP5 TNFRSF11A TNFRSF11B TNFSF11
26 bronchus cancer 10.0 ACP5 TNFRSF11A TNFRSF11B TNFSF11
27 bulbomembranous urethral cancer 10.0 ACP5 TNFRSF11A TNFRSF11B TNFSF11
28 atrial heart septal defect 10.0 CALCA PTH TNFRSF11A
29 toxicodendron dermatitis 10.0 BGLAP PTH
30 malignant giant cell tumor 10.0 ACP5 CSF1 TNFSF11
31 stickler syndrome 10.0 CALCA PTH TNFRSF11B
32 adult ependymoblastoma 10.0 BGLAP CALCA PTH
33 hypophosphatasia, adult 10.0 BGLAP CALCA PTH
34 mesenchymal cell neoplasm 10.0 BGLAP CALCA PTH
35 angioid streaks 10.0
36 developmental coordination disorder 10.0 ACP5 TNFSF11
37 opioid abuse 10.0 BGLAP CALCA PTH
38 pre-eclampsia 10.0 BGLAP CALCA PTH
39 impotence 9.9 CSF1 PTH TNFSF11
40 y chromosome detection 9.9 BGLAP PTH
41 tinea unguium 9.9 BGLAP CALCA PTH TNFRSF11B
42 ovarian endometrioid cystadenoma 9.9 B2M CALCA PTH
43 hypotrichosis 8 9.9 BGLAP PTH TNFRSF11B TNFSF11
44 maroteaux stanescu cousin syndrome 9.9 ACP5 BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
45 bile duct mucoepidermoid carcinoma 9.9 B2M PTH TNFRSF11B
46 prostate cancer 9.8
47 osteoporosis 9.8
48 iritis 9.8
49 prostatitis 9.8
50 osteitis fibrosa 9.8

Graphical network of the top 20 diseases related to Paget's Disease of Bone:



Diseases related to Paget's Disease of Bone

Symptoms & Phenotypes for Paget's Disease of Bone

UMLS symptoms related to Paget's Disease of Bone:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Paget's Disease of Bone:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.65 B2M CSF1 DCSTAMP OPTN PTH SQSTM1
2 limbs/digits/tail MP:0005371 9.1 PTH TNFRSF11A TNFRSF11B TNFSF11 VCP CSF1

Drugs & Therapeutics for Paget's Disease of Bone

Drugs for Paget's Disease of Bone (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 3 121268-17-5, 66376-36-1 2088
2
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
3
Pamidronate Approved Phase 4 40391-99-9 4674
4
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
5 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1
6 Calcium, Dietary Phase 4,Phase 3
7 vitamin d Phase 4,Phase 3
8 Trace Elements Phase 4,Phase 3
9 Diphosphonates Phase 4,Phase 3,Phase 1
10 Pharmaceutical Solutions Phase 4,Phase 3
11 Ergocalciferols Phase 4,Phase 3
12 Vitamins Phase 4,Phase 3
13 Micronutrients Phase 4,Phase 3
14 Vitamin D2 Nutraceutical Phase 4,Phase 3
15 Calciferol Nutraceutical Phase 4,Phase 3
16
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850
17
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
18
Etoposide Approved Phase 3 33419-42-0 36462
19
Cytarabine Approved, Investigational Phase 3,Phase 2 147-94-4 6253
20
Tamoxifen Approved Phase 3 10540-29-1 2733526
21
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
22
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
23
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
24
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
25
rituximab Approved Phase 3 174722-31-7 10201696
26
Etidronic acid Approved Phase 3,Phase 1 7414-83-7, 2809-21-4 3305
27
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
28
Lenograstim Approved Phase 3 135968-09-1
29
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
30
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
31
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
32
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
33
Carmustine Approved Phase 3 154-93-8 2578
34
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
35
Obinutuzumab Approved Phase 3 949142-50-1
36 tannic acid Approved, Nutraceutical Phase 3
37
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
38
Medroxyprogesterone Phase 3 520-85-4 10631
39 Risedronate Sodium Phase 3 115436-72-1
40 calcium channel blockers Phase 3
41 Alkylating Agents Phase 3,Phase 2
42 Selective Estrogen Receptor Modulators Phase 3
43 Contraceptive Agents Phase 3
44 Contraceptive Agents, Male Phase 3
45 Gemtuzumab Phase 2, Phase 3
46 Contraceptives, Oral Phase 3
47 Topoisomerase Inhibitors Phase 3,Phase 2
48 Hormone Antagonists Phase 3
49 Hormones Phase 3
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3

Interventional clinical trials:

(show all 31)
id Name Status NCT ID Phase
1 Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB) Completed NCT00774020 Phase 4
2 Re-treatment of Patients With Paget's Disease Using Zoledronic Acid Completed NCT00740129 Phase 4
3 Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Completed NCT00668200 Phase 4
4 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed NCT00159419 Phase 4
5 Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort Completed NCT00795483 Phase 4
6 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3
7 A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED) Completed NCT00480662 Phase 3
8 Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period Completed NCT00103740 Phase 3
9 Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period Completed NCT00051636 Phase 3
10 Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis Completed NCT00100620 Phase 3
11 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3
12 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00005589 Phase 3
13 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
14 Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV NSCLC Recruiting NCT02622607 Phase 3
15 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Active, not recruiting NCT01332968 Phase 3
16 Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI Completed NCT01140321 Phase 2
17 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2
18 Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Completed NCT00028496 Phase 1
19 Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) Recruiting NCT01585402 Phase 1
20 Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders Unknown status NCT00403598
21 Genetic Study of Families Affected by Paget's Disease of Bone Completed NCT00747994
22 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone Completed NCT00306046
23 Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism Completed NCT03027349
24 Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352) Completed NCT01077817
25 Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments Completed NCT00567502
26 Pathophysiology of Paget's Disease of Bone Recruiting NCT02802384
27 Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD) Recruiting NCT01353430
28 Characterization of Familial Myopathy and Paget Disease of Bone Recruiting NCT01166854
29 Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance − Active, not recruiting NCT02106455
30 Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: Terminated NCT00615628
31 Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma Terminated NCT01882231

Search NIH Clinical Center for Paget's Disease of Bone

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: osteitis deformans

Genetic Tests for Paget's Disease of Bone

Genetic tests related to Paget's Disease of Bone:

id Genetic test Affiliating Genes
1 Paget Disease of Bone 29 24 TNFRSF11A PDB4 SQSTM1 ZNF687
2 Paget Disease of Bone, Familial 29

Anatomical Context for Paget's Disease of Bone

MalaCards organs/tissues related to Paget's Disease of Bone:

39
Bone, Testes, Skin, Bone Marrow, Prostate, Monocytes, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Paget's Disease of Bone:

18
Vertebral Column, Skull, Pelvis, Set Of Limbs

Publications for Paget's Disease of Bone

Articles related to Paget's Disease of Bone:

(show top 50) (show all 572)
id Title Authors Year
1
NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone. ( 28506889 )
2017
2
A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis. ( 28524179 )
2017
3
Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone. ( 28324123 )
2017
4
A likely cranial osteodystrophy (Paget's disease of bone) in a Precolumbian, Mesoamerican stone sculpture. ( 28255822 )
2017
5
Adult Paget's disease of bone: a review. ( 28339664 )
2017
6
Total hip arthroplasty in patients with Paget's disease of bone: A systematic review. ( 28473965 )
2017
7
Proangiogenic gene polymorphisms are associated with susceptibility to Paget's disease of bone and with its clinical features. ( 28339363 )
2017
8
Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. ( 28054306 )
2017
9
Clinical and Genetic Advances in Paget's Disease of Bone: a Review. ( 28255281 )
2017
10
Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study. ( 28176386 )
2017
11
Antibody Response to Paramyxoviruses in Paget's Disease of Bone. ( 28361207 )
2017
12
Familial Early-Onset Paget's Disease of Bone Associated with a Novel hnRNPA2B1 Mutation. ( 28389692 )
2017
13
Epidemiology and pathology of Paget's disease of bone - aA review. ( 27600564 )
2016
14
Bone Quality in Paget's Disease of Bone. ( 26943142 )
2016
15
Development of a molecular test of Paget's disease of bone. ( 26772620 )
2016
16
Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. ( 27808435 )
2016
17
Environmental factors associated with familial or non-familial forms of Paget's disease of bone. ( 27932202 )
2016
18
Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. ( 27866237 )
2016
19
An unusual presentation of metastatic bone disease in a subject with Paget's disease of bone. ( 27843872 )
2016
20
Two diagnoses from bone marrow biopsy: multiple myeloma and Paget's disease of bone. ( 26912764 )
2016
21
Unusual presentation of Paget's disease of bone. ( 26944376 )
2016
22
Diagnosis and treatment of Paget's disease of bone : AA clinical practice guideline. ( 27600563 )
2016
23
IMAGES IN CLINICAL MEDICINE. Paget's Disease of Bone. ( 27028916 )
2016
24
The changing countenance of Paget's Disease of bone. ( 27068613 )
2016
25
Pathological fracture of the femur in a patient with Paget's disease of bone: a case report. ( 27516041 )
2016
26
Giant Cell Tumor Developing in Paget's Disease of Bone: A Case Report with Review of Literature. ( 28164066 )
2016
27
Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function. ( 27745697 )
2016
28
VAV3 Gene Polymorphism Is Associated with Paget's Disease of Bone. ( 27172236 )
2016
29
Paget's Disease of Bone: Approach to Its Historical Origins. ( 27061664 )
2016
30
Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review. ( 27193832 )
2016
31
Editorial: Paget's disease of bone. ( 27853907 )
2016
32
Asymptomatic Paget's disease of bone in a 62-year-old Nigerian man: three years post-alendronate therapy. ( 26870373 )
2016
33
Imaging of Paget's disease of bone. ( 27761746 )
2016
34
Computer-assisted quantitative evaluation of bisphosphonate treatment for Paget's disease of bone using the bone scan index. ( 28105116 )
2016
35
Paget's disease of bone-genetic and environmental factors. ( 26284446 )
2015
36
Periodontal disease in Paget's disease of bone. ( 26604949 )
2015
37
Paget's disease of bone: an osteoimmunological disorder? ( 26316708 )
2015
38
Genetics of Paget's disease of bone. ( 26587225 )
2015
39
Biology and Treatment of Paget's Disease of Bone. ( 26212817 )
2015
40
Targeted sequencing of the Paget's disease associated 14q32 locus identifies several missense coding variants in RIN3 that predispose to Paget's disease of bone. ( 25701875 )
2015
41
Treatment for Progressive Hearing Loss Due to Paget's Disease of Bone - A Case Report and Literature Review. ( 26915163 )
2015
42
Paget's Disease of Bone: Progress Towards Remission and Prevention. ( 26817293 )
2015
43
Evolution of Paget's disease of bone in adults inheriting SQSTM1 mutations. ( 25664955 )
2015
44
Paget's Disease of Bone among Various Ethnic Groups. ( 25685380 )
2015
45
Pathological fracture due to Paget's disease of bone. ( 25987126 )
2015
46
Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. ( 26807444 )
2015
47
Diagnosis and management of Paget's disease of bone. ( 25211441 )
2014
48
An Insight in to Paget's Disease of Bone. ( 24665195 )
2014
49
Conservative treatment of humeral fracture in a patient with Paget's disease of bone. ( 25524974 )
2014
50
Alternative splicing in osteoclasts and Paget's disease of bone. ( 25115182 )
2014

Variations for Paget's Disease of Bone

ClinVar genetic disease variations for Paget's Disease of Bone:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 SQSTM1 NM_003900.4(SQSTM1): c.1175C> T (p.Pro392Leu) single nucleotide variant Pathogenic/Likely pathogenic rs104893941 GRCh37 Chromosome 5, 179263445: 179263445
2 SQSTM1 NM_003900.4(SQSTM1): c.1224dupT (p.Glu409Terfs) duplication Pathogenic rs796051869 GRCh38 Chromosome 5, 179836494: 179836494
3 SQSTM1 NM_003900.4(SQSTM1): c.970_1165del single nucleotide variant Pathogenic rs796051870 GRCh38 Chromosome 5, 179833783: 179833783
4 SQSTM1 NM_003900.4(SQSTM1): c.1132A> T (p.Lys378Ter) single nucleotide variant Pathogenic rs796052213 GRCh38 Chromosome 5, 179833749: 179833749

Expression for Paget's Disease of Bone

Search GEO for disease gene expression data for Paget's Disease of Bone.

Pathways for Paget's Disease of Bone

GO Terms for Paget's Disease of Bone

Cellular components related to Paget's Disease of Bone according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 B2M BGLAP CALCA CSF1 PTH TNFRSF11B

Biological processes related to Paget's Disease of Bone according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 B2M BGLAP PTH TNFRSF11B
2 ossification GO:0001503 9.7 BGLAP TNFRSF11A TNFSF11
3 positive regulation of osteoclast differentiation GO:0045672 9.59 CSF1 TNFSF11
4 response to vitamin D GO:0033280 9.58 BGLAP PTH
5 monocyte chemotaxis GO:0002548 9.58 CALCA TNFRSF11A TNFSF11
6 mammary gland alveolus development GO:0060749 9.57 TNFRSF11A TNFSF11
7 regulation of osteoclast differentiation GO:0045670 9.56 BGLAP TNFSF11
8 positive regulation of ossification GO:0045778 9.55 CALCA PTH
9 response to inorganic substance GO:0010035 9.54 BGLAP TNFRSF11B
10 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.51 OPTN SQSTM1
11 positive regulation of macrophage differentiation GO:0045651 9.49 CALCA CSF1
12 positive regulation of bone resorption GO:0045780 9.48 DCSTAMP TNFSF11
13 negative regulation of bone resorption GO:0045779 9.46 CALCA TNFRSF11B
14 positive regulation of monocyte differentiation GO:0045657 9.43 CSF1 DCSTAMP
15 TNFSF11-mediated signaling pathway GO:0071847 9.37 TNFRSF11A TNFSF11
16 osteoclast proliferation GO:0002158 9.32 CSF1 TNFSF11
17 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.26 TNFRSF11A TNFSF11
18 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.16 TNFRSF11A TNFSF11
19 bone resorption GO:0045453 9.13 ACP5 PTH TNFSF11
20 osteoclast differentiation GO:0030316 8.92 CSF1 DCSTAMP TNFRSF11A TNFSF11

Molecular functions related to Paget's Disease of Bone according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 K63-linked polyubiquitin binding GO:0070530 8.62 OPTN SQSTM1

Sources for Paget's Disease of Bone

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....